Therefore, the development of effective therapeutic approaches that target the IRAK1/4-NF-κB pathway with TKIs could be considered an attractive option for the eradication of CML LSCs. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.